A Phase 3 interventional study of CycloSPORINE Ophthalmic and Intense Pulsed Light in Dry Eye and Contact Lens Complication, sponsored by Université de Sherbrooke. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-01.
Sponsored by Université de Sherbrooke · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 45 studies in Dry Eye Syndromes with a site in Canada — 5 open to participants now, 5 under way, 1 of them phase 3. Dry Eye Syndromes · Canada.
Among the 45 studies in Dry Eye Syndromes with a site in Canada, this one is the 22nd largest by planned enrollment of the 37 interventional ones that give a count, is one of 2 that started in 2024, is one of 4 in phase 3, and was the 41st registered.
1,370 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.
Browse Dry Eye Syndromes studies →5 of the 45 studies in Dry Eye Syndromes with a site in Canada are open now. Recruiting first, the newest first:
Pleryon Therapeutics (Hangzhou) Limited · Sites in Canada
Ages 18+
Centre hospitalier de l'Université de Montréal (CHUM) · Sites in Canada
Ages 18+ · Healthy volunteers
Reinhold Vieth · Sites in Canada
Ages 18+ · Healthy volunteers
Uptown Eye Specialists · Sites in Canada
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 117 Dry Eye Syndromes studies recruiting now, 74 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
45 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 44 is below the median of 60 across 1,132 interventional studies indexed under Dry Eye Syndromes.
Median enrollment 48 across the 37 interventional studies, 55 across the 8 observational. Of the 37 that completed or were terminated, 18 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 45 have an industry lead sponsor. The 10 most frequent:
Université de Sherbrooke is the lead sponsor of 298 studies on the registry; 67 are open to participants now.
Université de Sherbrooke has 2 studies filed under Dry Eye Syndromes — fewer than ten, so there is no comparison to draw.
1 of the studies in Dry Eye Syndromes with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07593404Pleryon Therapeutics (Hangzhou) LimitedEvaluation of a Novel Ocular Lubricating Eye Drop | 2026-11 |
Add it to your calendar (.ics) → With an account.
Among the 45 studies in Dry Eye Syndromes with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
In this study, two treatments typically used for dry eye disease will be tried for contact lens users to see if their symptoms when they use their contact lenses get better. Cyclosporine is a drop that is used for long-term management of the inflammation and Intense pulsed light (IPL) is a treatment done in a clinic to improve the health of the eyelid glands. The main question in this study is:
Does the combined treatment of cyclosporine and IPL improve the symptoms and the dry eye signs of contact lens wearers?
All the participants will receive the cyclosporine drops for 4 months twice a day. The research team will split the group of participants in two, half receiving the real IPL treatment and half receiving a sham IPL treatment during the last two months of the study. This will allow to compare the two groups to see how IPL helped. The dry eye tests will be done at the start of the study, after two months and after 4 months. The tests will include a dry eye symptoms questionnaire, measures on the tears, the structures of the front of the eye and the eyelids.
Dry eye disease is a complex and multifactorial pathology in which inflammation and changes to the tear film (instability and hyperosmolarity) play important roles. Dry eye disease is very common, with an estimated global prevalence of 11.59% although other analyses conclude to 50% of some populations suffering from dry eye. The condition has been traditionally classified in two subtypes: aqueous tear deficiency (secondary to a deficit of production by the lacrimal gland) and evaporative disease (secondary to a deficit of the lipid layer of the tear film), but when the condition progresses, almost all patients present characteristics of both subtypes. Meibomian gland dysfunction (MGD) is one of the conditions that is most frequently associated with dry eye disease and leads to evaporative dry eye and alterations of the ocular surface. The prevalence of MGD has been recently established between 21.2% and 29.5% in subjects of African and Caucasian race and higher among Arabs, Hispanics, and Asians. Many risk factors exist for dry eye disease and MGD, including age and usage of contact lens. Soft contact lenses (SCL) are used by hundreds of millions for visual correction. The wear of SCL, however, has the potential to create or worsen dry eye signs and symptoms. A comparative study has found that 39% of North-American wearers can be categorized as symptomatic of contact lens dry eye and the proportion of uncomfortable users increases with age. SCL wear can increase evaporative dry eye by weakening the lipid layer, which leads to decreased stability of the tear film and increased evaporation. It also contributes to aqueous dry eye etiology by reducing the tear volume. The wear of SCL has also been shown to have a damaging effect on meibomian glands and, in some cases, on the conjunctival goblet cells .
Arguments also support the role of SCL in the inflammation of the ocular surface, even in asymptomatic patients. Thus, dry eye disease associated with SCL wear is a complex condition that implies different mechanisms.
Cyclosporine A is a peptide produced by a fungus that has been used systemically for decades for its potent immunomodulatory effects. Usage for dry eye disease in a topical 0.05% oil-based formulation has been common since the early 2000s. On the ocular surface, cyclosporine acts by inhibiting calcineurin, which subsequently blocks the activation of T cells and prevents the release of cytokines, therefore reducing inflammation. It has been shown to increase tear volume, goblet cell density and to reduce surface staining as well as symptoms in dry eye patients. Divergent results have been observed on contact lens wearers, although one study has found an amplified effect on contact lens wearers symptomatic of dry eye when combining essential fatty acid supplements with topical cyclosporine. Despite having been shown useful in the management of dry eye disease, the oil-based formulation is considered having a low bioavailability. A new cyclosporine eyedrop has been approved in Canada and the USA in the recent past years and is based on nanomicelle technology with a concentration of 0.09%. This nano-micellar formulation could be more effective in delivering the cyclosporine to the tissues and have been shown to reduce ocular surface staining, to increase tear volume, and to be safe. Adverse events that are known to this product are mild, such as transient pain at instillation for about 23% of patients.
Intense pulsed light (IPL) is a therapeutic process that has been used for many years in dermatology and esthetics. The noncoherent pulses of light produce photo-biochemical effects and, in the treatment of dry eye disease, the application on the skin around the orbit to produces these effects on the meibomian glands and their surrounding tissue. The mechanisms by which IPL improves signs and symptoms of dry eye are not fully understood, but the melting of the meibum, the clogging of telangiectatic inflammatory vessels, the reduction of epithelial turnover, the improvement in the collagen synthesis, a mitochondrial activity enhancement (photo modulation), and the destruction of parasitic and bacterial species are the main theoretical explanations. IPL has been shown to be an effective therapeutic option to manage MGD.
Dozens of studies have shown that IPL reduces dry eye symptoms, increases tear break-up time, improves the secreting function of the glands as well as the quality of the meibum and reduces corneal staining. IPL is often combined with meibomian gland expression to maximize the therapeutic effects; however, controlled studies have shown that IPL is largely responsible of these effects and that it is the core mechanism of this combination. Two studies have observed the effect of IPL on SCL users, with the conclusion that it is an effective treatment for this population. IPL is considered to be a safe treatment.
Since SCL have been linked to both aqueous and evaporative etiologies or dry eye, this research project aims to study the effect of combining these two treatments to target the entirety of the tear film, believed to be essential to comfortable SCL wear. This study will be a randomized clinical trial that contains two interventions: the 0.09% cyclosporine eyedrops (Cequa) and IPL treatment. The main objective of this study is to establish if the treatment of contact lens related dry eyes by the combination of 0.09% cyclosporine for 16 weeks and a standard IPL treatment (3 sessions) is more effective in relieving dry eye symptoms when compared to 0.09% cyclosporine for 16 weeks with a sham IPL treatment (3 sessions). The secondary objectives are to compare the effects of each treatment combination (0.09% cyclosporine+IPL vs 0.09% cyclosporine+sham) on signs of dry eye, to explore the effects of cyclosporine 0.09% drops alone on contact lens wearers and to assess the security profile of these interventions on SCL wearers.
Based on prior data from the f-CLDEQ-8 validation study, a major study on the cyclosporine nanomicelle formulation and the first clinical trial on IPL for contact lens wearers, a sample size of 44 participants (22/group) was calculated to be necessary to detect a significant difference between the groups. 44 participants will thus be recruited from a primary care optometric clinic and nearby clinics. Participation to the study will require 5 visits from the participants. The first visit will be a collection of data and the dispensing of the 0.09% cyclosporine drops. 8 weeks later, the participants will present for their 2nd visit, during which data will be collected once again and participants will be randomized to either the treatment or the sham group and will receive their first treatment (IPL or sham accordingly to the assignation). The 2 following visits, 3 weeks apart, will be for the 2 last IPL/sham treatments. A final visit will be for data collection 2 weeks after the last IPL/sham treatment. Participants will take 0.09% cyclosporine for the whole 16 weeks.
A bilateral t-test for independent samples will be used to compare the difference in change on the f-CLDEQ-8 between groups on the 16 weeks interval. Concerning the dry eye signs, statistical treatment will be made to account for inter-eye correlation. Continuous variables will be analyzed using a multi-level model to assess the difference in change between groups on the 16 weeks interval. Discrete variable will be analyzed using a general linear model (GLM) for the same comparison. Data will be handled in an intent-to-treat way.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants will receive 0.09% cyclosporine drops dosed at bid for 16 weeks. Participants receive 3 IPL sessions at 3-weeks interval in the last 2 months of the study. IPL treatments will be given with Lumenis M22 with a 590nm filter, pulse duration of 6-50ms (3 pulses/trigger) and fluence will be determined after determining the skin type (Fitzpatrick scale) of the participant.
Drug: CycloSPORINE Ophthalmic · Procedure: Intense Pulsed Light
Participants will receive 0.09% cyclosporine drops dosed at bid for 16 weeks. Participants receive 3 IPL sessions at 3-weeks interval in the last 2 months of the study. IPL treatments will be given with Lumenis M22 with a 590nm filter, pulse duration of 6-50ms (3 pulses/trigger) and fluence will be determined set at 10 J/cm2. A plastic filter will recover the IPL prism, preventing the light to reach the skin of the participant.
Drug: CycloSPORINE Ophthalmic · Procedure: Sham Intense Pulse Light
Unidose of Cequa provided without charge to the participant. 1 drop in each eye morning and evening.
Also known as: Cequa
Appropriate eye patches and IPL gel will be applied. 15 triggers per passage will be applied from the right temple to the left temple (7 shots from the right temple to the right nose wing, 1 on the nose bridge and 7 shots from the left nose wing to the left temple). 2 passage/session will be applied.
Also known as: IPL M22 Lumenis
Appropriate eye patches and IPL gel will be applied. 15 triggers per passage will be applied with the plastic blocker mounted on the IPL prism from the right temple to the left temple (7 shots from the right temple to the right nose wing, 1 on the nose bridge and 7 shots from the left nose wing to the left temple). 2 passage/session will be applied.
Also known as: Sham-IPL M22 Lumenis
Contact lens dry eye symptoms
f-CLDEQ-8 questionnaire (French version of the Contact Lens Dry Eye Questionnaire - 8). Scores possible are from 1 to 37; higher score means more symptoms and worse dry eye
Time frame: Measured at each visit (Baseline, week 8, week 11, week 14 and week 16)
Global rating scale of change
Rating 0-100 of perceived comfort during contact lens wear in the past days; question sent by platform of ecological momentary assessment REDCap
Time frame: Tuesday and Saturday of every week for 16 consecutive weeks (while participating in the study)
Average number of hours spent wearing contact lenses
Question sent by platform of ecological momentary assessment REDCap
Time frame: Tuesday and Saturday of every week for 16 consecutive weeks (while participating in the study))
Artificial tear usage while wearing contact lenses
Question sent by platform of ecological momentary assessment REDCap
Time frame: Tuesday and Saturday of every week for 16 consecutive weeks (while participating in the study)
Non-invasive tear break-up time over contact lenses (pre-lens tear film)
Measured with the TFSQ NIBUT of the Medmont corneal topographer
Time frame: Baseline, week 8, and week 16
Non-invasive tear break-up time (natural tear film)
Measured with the TFSQ NIBUT of the Medmont E300 corneal topographer
Time frame: Baseline, week 8, and week 16
Tear break-up time
Average of 3 readings with fluorescein and observation through a slit lamp using cobalt and yellow filter
Time frame: Baseline, week 8, and week 16
Corneal staining score
Pictures of the cornea taken through an anterior segment imagery system (mounted on slit lamp) after fluorescein instillation. Pictures analyzed by automated AOS system, which counts the exact number of corneal punctate lesions
Time frame: Baseline, week 8, and week 16
Conjunctival staining score
Pictures of the nasal and temporal conjunctiva taken through an anterior segment imagery system (mounted on slit lamp) after lissamine green instillation. Pictures analyzed by masked experienced rater and graded using Efron grading scale (grade 0 to 4, a higher score meaning worse condition)
Time frame: Baseline, week 8, and week 16
Tear meniscus height (with contact lens in place)
Measured at the inferior meniscus with the Myah (Topcon) automated function before contact lens removal
Time frame: Baseline, week 8, and week 16
Tear osmolarity (with contact lens in place)
Measured on inferior palpebral conjunctiva with the iPen (i-Med) before contact lens removal
Time frame: Baseline, week 8, and week 16
Meibomian gland atrophy
Meibography scans performed on all 4 eyelids with the Lipiscan (Johnson \& Johnson) and sent to masked experienced rater for rating using the Meiboscore (Pult)
Time frame: Baseline and week 16
Adverse effects
Measured with home questionnaire containing 16 questions on adverse effects from both interventions
Time frame: Week 8, week 11, week 14, and week 16
Distance visual acuity
Variable measured for safety assessment. Snellen chart used with current correction (contact lens or glasses)
Time frame: Measured at each visit (Baseline, week 8, week 11, week 14 and week 16)
Intraocular pressure
Variable measured for safety assessment. Non-contact airpuff tonometer (Nidek RKT-7700)
Time frame: Measured at each visit (Baseline, week 8, week 11, week 14 and week 16)
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Raw data and individual participant data (denominalized) will be available upon reasonable demand to the research team. Protocol article will be submitted for publication
Supporting information: Study protocol, Statistical analysis plan
Time frame: Any time after publication of the results from this trial
Access criteria: Verified scholar; clearly stated motive and need for the data; plan to securely store the data.
Started Apr 2024 (actual). Primary completion is estimated for Sep 2025, 17 months after the start.
Of 96 phase 3 interventional studies under Dry Eye Syndromes, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 15. This study's planned 17 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.